BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 33199875)

  • 1. A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells.
    Nguyen GN; Everett JK; Kafle S; Roche AM; Raymond HE; Leiby J; Wood C; Assenmacher CA; Merricks EP; Long CT; Kazazian HH; Nichols TC; Bushman FD; Sabatino DE
    Nat Biotechnol; 2021 Jan; 39(1):47-55. PubMed ID: 33199875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors.
    Sabatino DE; Lange AM; Altynova ES; Sarkar R; Zhou S; Merricks EP; Franck HG; Nichols TC; Arruda VR; Kazazian HH
    Mol Ther; 2011 Mar; 19(3):442-9. PubMed ID: 21081906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs.
    Jiang H; Lillicrap D; Patarroyo-White S; Liu T; Qian X; Scallan CD; Powell S; Keller T; McMurray M; Labelle A; Nagy D; Vargas JA; Zhou S; Couto LB; Pierce GF
    Blood; 2006 Jul; 108(1):107-15. PubMed ID: 16522813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up of liver-directed, adeno-associated vector-mediated gene therapy in the canine model of hemophilia A.
    Batty P; Mo AM; Hurlbut D; Ishida J; Yates B; Brown C; Harpell L; Hough C; Pender A; Rimmer EK; Sardo Infirri S; Winterborn A; Fong S; Lillicrap D
    Blood; 2022 Dec; 140(25):2672-2683. PubMed ID: 35405003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver-restricted expression of the canine factor VIII gene facilitates prevention of inhibitor formation in factor VIII-deficient mice.
    Ishiwata A; Mimuro J; Mizukami H; Kashiwakura Y; Takano K; Ohmori T; Madoiwa S; Ozawa K; Sakata Y
    J Gene Med; 2009 Nov; 11(11):1020-9. PubMed ID: 19757487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotype correction of hemophilia A mice with adeno-associated virus vectors carrying the B domain-deleted canine factor VIII gene.
    Ishiwata A; Mimuro J; Kashiwakura Y; Niimura M; Takano K; Ohmori T; Madoiwa S; Mizukami H; Okada T; Naka H; Yoshioka A; Ozawa K; Sakata Y
    Thromb Res; 2006; 118(5):627-35. PubMed ID: 16371232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice.
    Sarkar R; Mucci M; Addya S; Tetreault R; Bellinger DA; Nichols TC; Kazazian HH
    Hum Gene Ther; 2006 Apr; 17(4):427-39. PubMed ID: 16610930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver-directed neonatal gene therapy.
    Xu L; Nichols TC; Sarkar R; McCorquodale S; Bellinger DA; Ponder KP
    Proc Natl Acad Sci U S A; 2005 Apr; 102(17):6080-5. PubMed ID: 15837921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete correction of hemophilia A with adeno-associated viral vectors containing a full-size expression cassette.
    Lu H; Chen L; Wang J; Huack B; Sarkar R; Zhou S; Xu R; Ding Q; Wang X; Wang H; Xiao W
    Hum Gene Ther; 2008 Jun; 19(6):648-54. PubMed ID: 18500941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A.
    Samelson-Jones BJ; Arruda VR
    Front Immunol; 2020; 11():618. PubMed ID: 32425925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of therapeutic levels of factor VIII in hemophilia A mice using a novel adeno/adeno-associated hybrid virus.
    Gnatenko DV; Wu Y; Jesty J; Damon AL; Hearing P; Bahou WF
    Thromb Haemost; 2004 Aug; 92(2):317-27. PubMed ID: 15269828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype.
    Sarkar R; Tetreault R; Gao G; Wang L; Bell P; Chandler R; Wilson JM; Kazazian HH
    Blood; 2004 Feb; 103(4):1253-60. PubMed ID: 14551134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A.
    Brown BD; Shi CX; Powell S; Hurlbut D; Graham FL; Lillicrap D
    Blood; 2004 Feb; 103(3):804-10. PubMed ID: 14512318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vector integration and fate in the hemophilia dog liver multiple years after AAV-FVIII gene transfer.
    Batty P; Fong S; Franco M; Sihn CR; Swystun LL; Afzal S; Harpell L; Hurlbut D; Pender A; Su C; Thomsen H; Wilson C; Youssar L; Winterborn A; Gil-Farina I; Lillicrap D
    Blood; 2024 Jun; 143(23):2373-2385. PubMed ID: 38452208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application.
    Monahan PE; Lothrop CD; Sun J; Hirsch ML; Kafri T; Kantor B; Sarkar R; Tillson DM; Elia JR; Samulski RJ
    Mol Ther; 2010 Nov; 18(11):1907-16. PubMed ID: 20700109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.
    Sun J; Hua B; Chen X; Samulski RJ; Li C
    Hum Gene Ther; 2017 Aug; 28(8):654-666. PubMed ID: 28478688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy.
    Finn JD; Ozelo MC; Sabatino DE; Franck HW; Merricks EP; Crudele JM; Zhou S; Kazazian HH; Lillicrap D; Nichols TC; Arruda VR
    Blood; 2010 Dec; 116(26):5842-8. PubMed ID: 20876851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A single adeno-associated virus (AAV)-murine factor VIII vector partially corrects the hemophilia A phenotype.
    Sarkar R; Xiao W; Kazazian HH
    J Thromb Haemost; 2003 Feb; 1(2):220-6. PubMed ID: 12871492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.
    Chuah MK; Schiedner G; Thorrez L; Brown B; Johnston M; Gillijns V; Hertel S; Van Rooijen N; Lillicrap D; Collen D; VandenDriessche T; Kochanek S
    Blood; 2003 Mar; 101(5):1734-43. PubMed ID: 12406898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene therapy for the hemophilias.
    VandenDriessche T; Collen D; Chuah MK
    J Thromb Haemost; 2003 Jul; 1(7):1550-8. PubMed ID: 12871290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.